Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

This results in the neuronal dysfunction and loss that ultimately leads to Parkinson’s disease. ... Currently, an estimated seven to ten million people are living with Parkinson’s across the globe, making it the second most common neurodegenerative

Latest news

  • Lilly buys biotech firm Disarm Therapeutics for $135m Lilly buys biotech firm Disarm Therapeutics for $135m

    trial. The anti-amyloid candidate, solanezumab, failed to improve outcomes for patients with dominantly inherited Alzheimer’s disease (DIAD) in a trial readout earlier this year. ... Solanezumab works by binding to soluble amyloid beta, allowing it to

  • FDA sets November date for expert panel review of Biogen’s aducanumab FDA sets November date for expert panel review of Biogen’s aducanumab

    Advisory committee will review biologics license application for controversial therapy. The US Food and Drug Administration (FDA) panel is set to review Biogen’s controversial Alzheimer’s disease treatment aducanumab on ... In August, Biogen picked

  • Stop that! Stop that!

    areas like Alzheimer’s disease. ... To be clear, this complex system’s view of their market was less comfortable than their reductionist view but it was a much more authentic one.

  • Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track Biogen’s highly-anticipated Alzheimers drug wins FDA fast-track

    Biogen has picked up a US Food and Drug Administration (FDA) fast-track review for its experimental Alzheimer’s disease treatment aducanumab. ... If approved, aducanumab will become the first treatment to reduce the clinical decline of Alzheimer’s

  • Biogen pays Denali $1bn upfront for Parkinson’s disease programme Biogen pays Denali $1bn upfront for Parkinson’s disease programme

    Mutations in the LRRK2 gene, a regulator of lysosomal function, can cause Parkinson’s disease and is thought to contribute to neurodegeneration. ... Biogen is currently awaiting a decision on its controversial Alzheimer’s disease therapy aducanumab

More from news
Approximately 119 fully matching, plus 405 partially matching documents found.

Latest Intelligence

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    and Alzheimer’s diseases. ... It’s snakes and ladders. “The world is not abandoning neuroscience. It is just recognising that it is tricky and difficult.”.

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... big diseases in the field, such as Alzheimer’s, is too limited to make near-term success likely.

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimers disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... Most of us will have experience of family or friends with Alzheimer’s or

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    That’s not dampening enthusiasm for the emerging field, however, and by some estimates, just about every big pharma company is active. ... C4 also has a collaboration in place with Biogen focusing on neurological conditions such as Alzheimer’s

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    Research into treatments for Alzheimer’s has become disappointingly predictable, with trials and candidates in the area regularly abandoned following underwhelming results. ... It was just another in a string of late-stage failures in Alzheimer’s

More from intelligence
Approximately 8 fully matching, plus 41 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 20 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics